Alligator meets primary endpoint with CD40 agonist in pancreatic cancer - Søren Bregenholt , CEO, Alligator Bioscience 00:00:00
Søren Bregenholt – born 1971, Chief Executive Officer – holds a PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration and co-development agreements. Employed since June 2021 and member of the Management Team since 2021.
